Cutera's enlighten Laser Platform Cleared by FDA for Acne Scar Treatment

Cutera's enlighten Laser Platform Cleared by FDA for Acne Scar Treatment
 
Cutera, Inc. announced today the U.S. Food and Drug Administration (FDA) cleared the enlighten Laser Platform for treating acne scars. The enlighten was already FDA cleared for tattoo removal and the treatment of benign pigmented lesions.
 
According to the company,  Acne affects approximately 650,000,000 people, 40% of whom will have some form of acne scarring.
 
Cutera is adding PICO Genesis FX, a new application to the enlighten Laser Platform, in January, 2019.  
 
In a recent study of over 100 treatments, 97% of patients treated with Pico Genesis FX saw mild to moderate improvement in acne scars with minimal patient downtime and side effects on all skin types. In addition, the study revealed statistically significant improvement in skin radiance, smoothness, pigmentation, erythema, and pore size.
 
Dr. Neil Sadick, of Sadick Dermatology, New York, NY stated, “PICO Genesis FX elevates enlighten’s existing skin revitalization capabilities and introduces a fractional approach to treating acne scars, textural concerns and aging skin on all skin types. Its novel Micro Lens Array (MLA) treats the upper layers of the epidermis and dermis which generate collagen stimulation and remodeling of the skin. The expansion of this new fractional treatment means my patients will receive more efficacious results with little-to-no downtime for active lifestyles.”